JP2018535996A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018535996A5 JP2018535996A5 JP2018528591A JP2018528591A JP2018535996A5 JP 2018535996 A5 JP2018535996 A5 JP 2018535996A5 JP 2018528591 A JP2018528591 A JP 2018528591A JP 2018528591 A JP2018528591 A JP 2018528591A JP 2018535996 A5 JP2018535996 A5 JP 2018535996A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- composition
- acceptable salt
- effective amount
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562263582P | 2015-12-04 | 2015-12-04 | |
| US62/263,582 | 2015-12-04 | ||
| US201662342755P | 2016-05-27 | 2016-05-27 | |
| US201662342727P | 2016-05-27 | 2016-05-27 | |
| US62/342,755 | 2016-05-27 | ||
| US62/342,727 | 2016-05-27 | ||
| US201662371145P | 2016-08-04 | 2016-08-04 | |
| US62/371,145 | 2016-08-04 | ||
| PCT/US2016/064824 WO2017096303A2 (en) | 2015-12-04 | 2016-12-02 | Cerdulatinib for treating hematological cancers |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018535996A JP2018535996A (ja) | 2018-12-06 |
| JP2018535996A5 true JP2018535996A5 (cg-RX-API-DMAC7.html) | 2020-01-09 |
| JP6944936B2 JP6944936B2 (ja) | 2021-10-06 |
Family
ID=57614468
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018528591A Expired - Fee Related JP6944936B2 (ja) | 2015-12-04 | 2016-12-02 | 血液癌を処置するためのセルデュラチニブ |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US10736895B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3383396B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6944936B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN108367006B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2016363005A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2950640A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2959692T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2017096303A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7258462B2 (ja) | 2015-05-29 | 2023-04-17 | ポートラ ファーマシューティカルズ， エルエルシー | Ｂ細胞悪性腫瘍の治療のためのセルデュラチニブ |
| JP6833816B2 (ja) | 2015-08-12 | 2021-02-24 | ポートラ ファーマシューティカルズ， インコーポレイテッド | 骨髄腫を治療するためのセルデュラチニブ（ｃｅｒｄｕｌａｔｉｎｉｂ） |
| RU2020124293A (ru) * | 2018-01-09 | 2022-02-10 | Дермавант Саенсиз Гмбх | Фармацевтические композиции для местного нанесения на кожу, содержащие цердулатиниб, и их применение |
| JP2021523114A (ja) * | 2018-05-04 | 2021-09-02 | ポートラ ファーマシューティカルズ， インコーポレイテッド | リンパ腫の治療方法 |
| US10865198B2 (en) | 2018-05-04 | 2020-12-15 | Alexion Pharmaceuticals, Inc. | Solid forms of cerdulatinib |
| US10851087B2 (en) | 2018-05-04 | 2020-12-01 | Portola Pharmaceuticals, Inc. | Synthesis of cerdulatinib |
| SG11202108770TA (en) * | 2019-02-15 | 2021-09-29 | Janssen Biotech Inc | Combination therapy for treatment of b-cell malignancies |
| JP2023529313A (ja) * | 2020-05-26 | 2023-07-10 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 低悪性度ｂ細胞リンパ腫における循環ｂ細胞亜集団 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999031073A1 (en) | 1997-12-15 | 1999-06-24 | Yamanouchi Pharmaceutical Co., Ltd. | Novel pyrimidine-5-carboxamide derivatives |
| TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| US7449456B2 (en) | 2002-06-28 | 2008-11-11 | Astellas Pharma, Inc. | Diaminopyrimidinecarboxamide derivative |
| JP2009544592A (ja) | 2006-07-21 | 2009-12-17 | ノバルティス アクチエンゲゼルシャフト | Ｊａｋキナーゼ阻害剤としての２，４−ジ（アリールアミノ）−ピリミジン−５−カルボキサミド化合物 |
| ES2616789T3 (es) | 2006-09-22 | 2017-06-14 | Pharmacyclics, Inc. | Inhibidores de tirosina cinasa de Bruton |
| CA2960692C (en) | 2008-04-16 | 2019-09-24 | Portola Pharmaceuticals, Inc. | 2,6-diamino-pyrimidin-5-yl-carboxamides as syk or jak kinase inhibitors |
| US8138339B2 (en) | 2008-04-16 | 2012-03-20 | Portola Pharmaceuticals, Inc. | Inhibitors of protein kinases |
| AR076550A1 (es) | 2009-05-06 | 2011-06-22 | Portola Pharm Inc | Inhibidores de la janus tirosina kinasa (jak) |
| PL2435432T6 (pl) | 2009-05-26 | 2024-02-12 | Abbvie Ireland Unlimited Company | Środki wywołujące apoptozę do leczenia raka oraz chorób immunologicznych i autoimmunologicznych |
| CA2780759A1 (en) | 2009-12-01 | 2011-06-09 | Rigel Pharmaceuticals, Inc. | Protein kinase c inhibitors and uses thereof |
| US9357229B2 (en) | 2010-07-28 | 2016-05-31 | Qualcomm Incorporated | Coding motion vectors in video coding |
| EP2621489A1 (en) | 2010-09-30 | 2013-08-07 | Portola Pharmaceuticals, Inc. | Combinations of 4-(cyclopropylamino)-2-(4-(4-(ethylsulfonyl)piperazin-1-yl)phenylamino)pyrimidine-5-carboxamide and fludarabine |
| SI2643322T1 (en) | 2010-11-23 | 2018-01-31 | Abbvie Inc. | Salts and crystalline forms of an apoptosis-inducing agent |
| CA2844507A1 (en) | 2011-08-10 | 2013-02-14 | Novartis Pharma Ag | Jak pi3k/mtor combination therapy |
| BR112015001690A2 (pt) | 2012-07-24 | 2017-11-07 | Pharmacyclics Inc | mutações associadas com a resistência a inibidores da tirosina quinase de bruton (btk) |
| EP2903970A4 (en) | 2012-10-08 | 2016-11-30 | Portola Pharm Inc | SUBSTITUTED PYRIMIDINYL KINASE INHIBITORS |
| CA2890111A1 (en) | 2012-11-02 | 2014-05-08 | Pharmacyclics, Inc. | Tec family kinase inhibitor adjuvant therapy |
| EP3191098A4 (en) | 2014-09-12 | 2018-04-25 | G1 Therapeutics, Inc. | Combinations and dosing regimes to treat rb-positive tumors |
| JP7258462B2 (ja) | 2015-05-29 | 2023-04-17 | ポートラ ファーマシューティカルズ， エルエルシー | Ｂ細胞悪性腫瘍の治療のためのセルデュラチニブ |
| JP6833816B2 (ja) | 2015-08-12 | 2021-02-24 | ポートラ ファーマシューティカルズ， インコーポレイテッド | 骨髄腫を治療するためのセルデュラチニブ（ｃｅｒｄｕｌａｔｉｎｉｂ） |
| US10865198B2 (en) | 2018-05-04 | 2020-12-15 | Alexion Pharmaceuticals, Inc. | Solid forms of cerdulatinib |
-
2016
- 2016-12-02 CA CA2950640A patent/CA2950640A1/en not_active Abandoned
- 2016-12-02 WO PCT/US2016/064824 patent/WO2017096303A2/en not_active Ceased
- 2016-12-02 EP EP16819235.9A patent/EP3383396B1/en active Active
- 2016-12-02 CN CN201680073276.XA patent/CN108367006B/zh active Active
- 2016-12-02 JP JP2018528591A patent/JP6944936B2/ja not_active Expired - Fee Related
- 2016-12-02 US US15/780,414 patent/US10736895B2/en active Active
- 2016-12-02 AU AU2016363005A patent/AU2016363005A1/en not_active Abandoned
- 2016-12-02 ES ES16819235T patent/ES2959692T3/es active Active
-
2020
- 2020-07-16 US US16/931,038 patent/US11446300B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018535996A5 (cg-RX-API-DMAC7.html) | ||
| Dréan et al. | PARP inhibitor combination therapy | |
| Liu et al. | Raltitrexed-based chemotherapy for advanced colorectal cancer | |
| Wang et al. | Targeting Bruton's tyrosine kinase with ibrutinib in B‐cell malignancies | |
| Kritharis et al. | Lenalidomide in non-Hodgkin lymphoma: biological perspectives and therapeutic opportunities | |
| JP2018520117A5 (cg-RX-API-DMAC7.html) | ||
| JP2019502669A5 (cg-RX-API-DMAC7.html) | ||
| Spigel et al. | Efficacy and safety of oral topotecan and bevacizumab combination as second-line treatment for relapsed small-cell lung cancer: an open-label multicenter single-arm phase II study | |
| JP2018524347A5 (cg-RX-API-DMAC7.html) | ||
| JP2019526595A5 (cg-RX-API-DMAC7.html) | ||
| WO2010136394A1 (en) | Therapeutic combination comprising a plk1 inhibitor and an antineoplastic agent | |
| EP2501385B1 (en) | Therapeutic combination comprising a cdc7 inhibitor and an antineoplastic agent | |
| Dawar et al. | The emerging role of lenalidomide in the management of mantle cell lymphoma (MCL) | |
| Coyne et al. | Delivering on the promise: poly ADP ribose polymerase inhibition as targeted anticancer therapy | |
| Anderson et al. | Fludarabine: a review of its use in non-Hodgkin’s lymphoma | |
| Waldron et al. | Pharmacokinetic and pharmacodynamic considerations in the treatment of chronic lymphocytic leukemia: ibrutinib, idelalisib, and venetoclax | |
| JP2017506259A5 (cg-RX-API-DMAC7.html) | ||
| Rummel et al. | Bendamustine's emerging role in the management of lymphoid malignancies | |
| JP2018506533A5 (cg-RX-API-DMAC7.html) | ||
| Kovács et al. | Long-term quality of life after intensified multi-modality treatment of oral cancer including intra-arterial induction chemotherapy and adjuvant chemoradiation | |
| Forcello et al. | Idelalisib: the first-in-class phosphatidylinositol 3-kinase inhibitor for relapsed CLL, SLL, and indolent NHL | |
| WO2025061140A1 (zh) | 治疗非霍奇金淋巴瘤的药物组合及其用途 | |
| Sarantopoulos et al. | Safety and pharmacokinetics of cabazitaxel in patients with hepatic impairment: a phase I dose-escalation study | |
| Park et al. | Combination chemotherapy with paclitaxel and ifosfamide as the third-line regimen in patients with heavily pretreated small cell lung cancer | |
| Burnett et al. | A Phase 2a Open-Label Study to Investigate Safety and Tolerability (including the MTD), Efficacy, Pharmacokinetics, Pharmacodynamics and Immunogenicity of MT-3724 in Combination with Gemcitabine and Oxaliplatin in Subjects with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma |